DE69901099T2 - Verwendung von interferon alpha 5 in der behandlung viraler hepatopathien - Google Patents

Verwendung von interferon alpha 5 in der behandlung viraler hepatopathien

Info

Publication number
DE69901099T2
DE69901099T2 DE69901099T DE69901099T DE69901099T2 DE 69901099 T2 DE69901099 T2 DE 69901099T2 DE 69901099 T DE69901099 T DE 69901099T DE 69901099 T DE69901099 T DE 69901099T DE 69901099 T2 DE69901099 T2 DE 69901099T2
Authority
DE
Germany
Prior art keywords
livers
treatment
alpha
viral
sub
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69901099T
Other languages
English (en)
Other versions
DE69901099D1 (de
DE69901099T4 (de
Inventor
Valtuena Jes S Prieto
Murillo M Pilar Civeira
Leoz Esther Larrea
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Instituto Cientifico y Tecnologico de Navarra SA
Original Assignee
Instituto Cientifico y Tecnologico de Navarra SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instituto Cientifico y Tecnologico de Navarra SA filed Critical Instituto Cientifico y Tecnologico de Navarra SA
Publication of DE69901099T2 publication Critical patent/DE69901099T2/de
Application granted granted Critical
Publication of DE69901099T4 publication Critical patent/DE69901099T4/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/212IFN-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
DE69901099T 1998-05-13 1999-05-13 Verwendung von interferon alpha 5 in der behandlung viraler hepatopathien Expired - Lifetime DE69901099T4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES009801003A ES2138565B1 (es) 1998-05-13 1998-05-13 Uso del interferon alfa 5 en el tratamiento de las hepatopatias viral es.
PCT/ES1999/000134 WO1999058143A1 (es) 1998-05-13 1999-05-13 Uso del interferon alfa 5 en el tratamiento de las hepatopatias virales

Publications (2)

Publication Number Publication Date
DE69901099T2 true DE69901099T2 (de) 2002-11-07
DE69901099T4 DE69901099T4 (de) 2003-03-13

Family

ID=8303773

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69901099T Expired - Lifetime DE69901099T4 (de) 1998-05-13 1999-05-13 Verwendung von interferon alpha 5 in der behandlung viraler hepatopathien
DE69901099A Expired - Lifetime DE69901099D1 (de) 1998-05-13 1999-05-13 Verwendung von interferon alpha 5 in der behandlung viraler hepatopathien

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69901099A Expired - Lifetime DE69901099D1 (de) 1998-05-13 1999-05-13 Verwendung von interferon alpha 5 in der behandlung viraler hepatopathien

Country Status (15)

Country Link
US (2) US6995133B1 (de)
EP (1) EP1077068B9 (de)
JP (1) JP2002514606A (de)
CN (1) CN1173738C (de)
AT (1) ATE214941T1 (de)
AU (1) AU753463B2 (de)
BR (1) BR9911774A (de)
CA (1) CA2335645C (de)
DE (2) DE69901099T4 (de)
DK (1) DK1077068T5 (de)
ES (2) ES2138565B1 (de)
PT (1) PT1077068E (de)
RU (1) RU2209079C2 (de)
SE (1) SE1077068T5 (de)
WO (1) WO1999058143A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110179530A1 (en) * 2001-01-23 2011-07-21 University Of Central Florida Research Foundation, Inc. Pharmaceutical Proteins, Human Therapeutics, Human Serum Albumin Insulin, Native Cholera Toxin B Subunit on Transgenic Plastids
FR2824333B1 (fr) * 2001-05-03 2003-08-08 Genodyssee Nouveaux polynucleotides et polypeptides de l'ifn alpha 5
ES2303492A1 (es) * 2004-08-18 2008-08-01 Instituto Cientifico Y Tecnologico De Navarra S.A. Uso del factor de crecimiento semejante a la insulina tipo i y de interferon alfa en el tratamiento de una enfermedad hepatica cronica, kit y composiciones que los comprenden.
WO2006032711A1 (es) * 2004-08-18 2006-03-30 Instituto Científico Y Tecnológico De Navarra S.A. Uso del factor de crecimiento semejante a la insulina tipo i y de interferón alfa en el tratamiento de una enfermedad hepática crónica, kit y composiciones que los comprenden
MX2012008893A (es) * 2010-02-01 2013-02-27 Digna Biotech Sl Procedimiento para la produccion de interferon alfa 5.
BR112013032188A2 (pt) 2011-06-23 2016-12-20 Digna Biotech Sl composição, produto e método para tratar pacientes com hepatite c crônica
LT6164B (lt) 2013-10-15 2015-06-25 Uab Biotechnologinės Farmacijos Centras "Biotechpharma" Sulieti interferono-alfa 5 baltymai su kitu citokinu ir jų gamybos būdas

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4973479A (en) * 1982-01-15 1990-11-27 Cetus Corporation Interferon-α61
ATE193724T1 (de) * 1991-03-12 2000-06-15 Biogen Inc Cd2 bindender bereich für das lymphocyten- funktion assoziierte antigen-3
DK0741577T3 (da) * 1994-03-07 2003-02-17 Imperial College Anvendelsen af enterferon, subtype alfa 8, til fremstilling af lægemidler til behandling af virusinfektioner i leveren
US6172046B1 (en) * 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection

Also Published As

Publication number Publication date
PT1077068E (pt) 2002-07-31
EP1077068B1 (de) 2002-03-27
AU753463B2 (en) 2002-10-17
CA2335645C (en) 2011-01-04
EP1077068B9 (de) 2002-10-02
US20060188477A1 (en) 2006-08-24
SE1077068T3 (sv) 2002-07-02
ATE214941T1 (de) 2002-04-15
ES2174604T3 (es) 2002-11-01
CN1173738C (zh) 2004-11-03
CN1307482A (zh) 2001-08-08
DE69901099D1 (de) 2002-05-02
EP1077068A1 (de) 2001-02-21
RU2209079C2 (ru) 2003-07-27
US6995133B1 (en) 2006-02-07
JP2002514606A (ja) 2002-05-21
BR9911774A (pt) 2001-02-06
DK1077068T3 (da) 2002-07-22
ES2138565B1 (es) 2000-08-16
ES2138565A1 (es) 2000-01-01
WO1999058143A9 (es) 2002-08-22
US7501392B2 (en) 2009-03-10
DE69901099T4 (de) 2003-03-13
DK1077068T5 (da) 2002-10-14
SE1077068T5 (sv) 2003-03-04
CA2335645A1 (en) 1999-11-18
WO1999058143A1 (es) 1999-11-18
AU3711199A (en) 1999-11-29

Similar Documents

Publication Publication Date Title
PT725824E (pt) Epitopos de celulas t humanas imunodominantes do virus da hepatite c
AU8700291A (en) Hcv-specific peptides, agents therefor and the use thereof
DE60324552D1 (en) Substituierte cycloalkyl p1' hepatitis c virus inhibitoren
DK0386734T3 (da) Immunogene regioner på E-7-proteinet af humant papillomavirus type 16
BR9913406A (pt) Processo de tratamento de infecção causada por pelo menos um vìrus da famìlia flaviviridae e de doença associada com a citada infecção em um hospedeiro vivo possuindo a citada infecção
ATE552340T1 (de) Hepatitis c virus genotypsequenzen sowie ihre verwendung als behandlungs- und nachweismitteln
ATE478944T1 (de) Zytokin ligand zur behandlung von asthma und atemwegsüberreaktivität
DE69839812D1 (de) Analoge des menschlichen interferon-alpha mit niedriger toxizität
ATE171710T1 (de) Hcv peptidantigene und verfahren zur bestimmung von hcv
DE69901099T4 (de) Verwendung von interferon alpha 5 in der behandlung viraler hepatopathien
DE69937269D1 (de) Bioaktive Peptide, ihre Verwendung und Verfahren zu ihre Herstellung
DK1501936T3 (da) Familie af cytokin-proteiner
CA2334941A1 (en) Tnf-derived peptides for use in treating oedema
KR920012114A (ko) 사람 면역결핍 바이러스(HIV)의 그룹-특이 항원(gaa)의 선택된 펩타이드, 이의 제법 및 용도
DE69824001D1 (de) Reagenz zum nachweis und weiterverfolgen von virusinfektionen
DK708488D0 (da) Faktor i praeparat
ATE375390T1 (de) G-protein-gekoppelter rezeptor-ähnliche proteine
KR950000880A (ko) 한국형 씨(c)형 간염 바이러스의 일종인 케이에이치씨브이-엘2(khcv-l2)의 전체 뉴클레오티드서열 및 이로부터 유추된 아미노산 서열
IT1270941B (it) Peptidi di hcv e loro usi.
ATE432985T1 (de) Polypeptide mit aktivität der stimulierung von neutrophilen
FI981381A (fi) Menetelmä HCV-polypeptidien valmistamiseksi
KR950000881A (ko) 새로운 한국형 씨(C)형 간염 바이러스 씨디엔에이(cDNA) 절편의 뉴클레오티드 서열 및 이로부터 유추된 아미노산 서열
ATE459708T1 (de) Herstellung von infektiöser respiratorischer synzitial virus aus klonierten nukleotid sequenzen